Geron (GERN)

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

GERN stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
Low target
High target
B. Riley Securities
28 Jul 22
10 May 22


9 May 22
9 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 31.33M 31.33M 31.33M 31.33M 31.33M 31.33M
Cash burn (monthly) 1.18M 17.67K 9.56M 9.52M 11.32M 8.07M
Cash used (since last report) 5.09M 76.14K 41.19M 41.02M 48.81M 34.76M
Cash remaining 26.23M 31.25M -9.87M -9.7M -17.48M -3.44M
Runway (months of cash) 22.2 1768.8 -1.0 -1.0 -1.5 -0.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Jul 22 Faye Feller Employee Stock Option Common Stock Grant Acquire A No No 1.93 120,000 231.6K 120,000
30 Jun 22 Spiegel Robert J. Common Stock Grant Acquire A No No 0 4,637 0 145,652
30 Jun 22 Anil Kapur Common Stock Grant Acquire A No No 1.11 13,062 14.5K 47,195
10 May 22 Bir Dawn Carter Stock Option Common Stock Grant Acquire A No No 1.48 125,000 185K 125,000
53.8% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 150 149 +0.7%
Opened positions 22 20 +10.0%
Closed positions 21 12 +75.0%
Increased positions 43 44 -2.3%
Reduced positions 34 39 -12.8%
13F shares Current Prev Q Change
Total value 291.74M 323.38M -9.8%
Total shares 202.97M 159.25M +27.4%
Total puts 167.2K 299.9K -44.2%
Total calls 4.24M 1.24M +243.2%
Total put/call ratio 0.0 0.2 -83.8%
Largest owners Shares Value Change
Ra Capital Management 30.13M $40.97M 0.0%
BLK Blackrock 24.58M $33.43M -2.5%
Growth Equity Opportunities 17 20.19M $33.12M 0.0%
Vanguard 17.34M $23.58M +12.4%
NEA Management 16.32M $22.19M +21.2%
Vivo Capital 15.24M $20.72M NEW
TCG Crossover Management 14.29M $19.43M NEW
EcoR1 Capital 14.29M $19.43M +48.6%
STT State Street 13.52M $18.39M +13.4%
MPM Oncology Impact Management 6.15M $8.36M +9.3%
Largest transactions Shares Bought/sold Change
Vivo Capital 15.24M +15.24M NEW
TCG Crossover Management 14.29M +14.29M NEW
EcoR1 Capital 14.29M +4.67M +48.6%
NEA Management 16.32M +2.86M +21.2%
Vanguard 17.34M +1.91M +12.4%
Sofinnova Investments 1.9M +1.9M NEW
STT State Street 13.52M +1.59M +13.4%
FMR 195.61K -1.55M -88.8%
Millennium Management 2.17M +1.48M +217.6%
HealthCor Management 900K +900K NEW

Financial report summary

Management Discussion
  • Our results of operations have fluctuated from period to period and may continue to fluctuate in the future. Results of operations for any period may be unrelated to results of operations for any other period. Thus, historical results should not be viewed as indicative of future operating results.
  • We are subject to risks common to companies in our industry and at our stage of development, including, but not limited to, risks inherent in research and development efforts, including the development, manufacture, regulatory approval for and commercialization of, imetelstat; uncertainty of non-clinical and clinical trial results or regulatory approvals or clearances; the future development of imetelstat by us, including any future efficacy or safety results that may cause the benefit-risk profile of imetelstat to become unacceptable; the uncertain and unpredictable drug research and discovery process; overcoming disruptions and/or delays due to the COVID-19 pandemic or geopolitical events; our need for substantial additional capital; enforcement of our patent and proprietary rights; reliance upon our CROs, contract manufacturing organizations, or CMOs, consultants, licensees, investigators and other third parties; and potential competition. In order for imetelstat to be commercialized, we must conduct non-clinical tests and clinical trials to demonstrate the safety and efficacy of imetelstat, obtain regulatory approvals or clearances and enter into manufacturing, distribution and marketing arrangements, as well as obtain market acceptance. We do not expect to receive revenue based on sales of imetelstat for many years, if at all.
  • We previously entered into license or collaboration agreements with companies involved with oncology, diagnostics, research tools and biologics production, whereby we granted certain rights to our non-imetelstat related technologies. As of December 31, 2020, our license agreements related to our human telomerase reverse transcriptase, or hTERT, technology have been terminated or expired due to patent expirations on such technology. The remaining active license agreement was a license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides. This license was terminated effective April 2021. In connection with these agreements, we were eligible to receive license fees, option fees, milestone payments and royalties on future sales of products, or any combination thereof. Also, in connection with the divestiture of Geron’s human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales from certain research or commercial products utilizing Geron’s divested intellectual property.

Content analysis

H.S. junior Avg
New words: abnormality, absent, accommodate, adapt, adware, AG, alleviate, antibribery, anticorruption, argument, attack, Australian, average, bad, booster, bribery, Bristol, British, chromosomal, confusion, conversion, deletion, destroy, destruction, deteriorate, disaster, DISC, disparate, dollar, downturn, earthquake, elraglusib, email, error, expenditure, exploitable, extortion, fifteen, fire, fourteen, geopolitical, GlaxoSmithKline, glycogen, hardware, hemojuvelin, HHS, HIPAA, HITECH, HJV, IND, inquiry, instability, insurrection, intercompany, interleukin, intermediate, irrevocably, labor, LD, living, macroeconomic, military, misuse, modulator, monoclonal, monthly, nearby, oppose, plc, posture, pound, processor, proliferation, ransomware, retaliatory, retroactive, Rigel, Roivant, Russia, sabatolimab, scrutinize, server, ship, shipping, stipulation, synthase, transmission, transmit, Ukraine, uncontrolled, UNREGISTERED, unrest, unsuitable, Vonjo, water, weather, widespread
Removed: adequacy, Asia, backbone, bound, breakdown, building, burdensome, callable, capability, ceased, certified, CJEU, Commerce, Commissioner, corrective, CR, criterion, damage, damaged, deceptive, declared, declining, degrade, delivering, Department, died, disable, documentation, dosed, East, enacting, exemplify, expansive, expensed, explicit, framework, free, futility, gradual, gradually, granting, hemoglobin, interdependent, intrusion, IWG, Justice, launched, LCL, liable, mandating, mark, merger, Middle, misrepresentative, mitigate, network, Nonrefundable, North, opened, operative, optimal, originally, outreach, packed, paragraph, pharmacoeconomic, phishing, posted, PR, pretreatment, preventative, producing, progression, proportion, published, putative, QUALITATIVE, QUANTITATIVE, randomized, RBC, reach, reevaluate, remeasured, remedial, remediation, residency, reverse, revoked, robust, sabotage, selective, shared, Shield, Sienna, South, split, statute, stopping, Subtopic, supervisory, Switzerland, transcriptase, transferred, trend, unfair, validated, validation, verify, vulnerability